Oppenheimer analyst Leland Gershell maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...

Catalyst Pharma (CPRX) Company Description: Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare ...

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Thank you for standing by. My name is Kris and I will be your conference operator today. At this time, I would like to welcome everyone to ...

The growth in female representation in South Dakota is part of a trend nationally, though most legislatures don’t have gender ...

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic ...

A proposed US$8.9bil carbon-capture pipeline that has polarised the US Corn Belt has hit another setback in the critical ...

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) recently filed a Form 8-K with the Securities and Exchange Commission, detailing its financial performance for the third quarter of 2024. The company ...

Catalyst制药的第三季度财务业绩显示公司正在蓬勃发展,其罕见病治疗药物的收入增加,市场地位强劲。公司的战略计划和对患者护理的关注表明未来增长前景乐观,这也反映在上调的全年收入指引中。随着Catalyst继续扩大国内外业务,投资者可能会关注其临床和运营策略对长期业绩的影响。